Method and materials for sensitizing neoplastic tissue to radiation
US4894364A · kind A · utility
Inventor
Key dates
| Filing date | Jun 24, 1985 |
| Grant date | Jan 16, 1990 |
| Priority date | — |
| Expiry date | Jun 24, 2005 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N2005/1098
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Tumors are sensitized to radiation by administration of 5-chlorodeoxycytidine (5-CldC) or 5-halo-2'-halo-2'-deoxy-cytidine or -uridine derivatives. Tetrahydrouridane (H.sub.4 U) and/or 2'-deoxytetrahydrouridine (dH.sub.4 U) is preferably coadministered with the deoxycytidine derivative to inhibit deamination of the deoxycytidine derivatives. Optional pre- or concurrent treatment with agents to reduce the amount of competing metabolites to favor CldC, such as 5-fluorodeoxyuridine, results in a procedure that significantly increases the dose effects of X-radiation. Pharmaceutical compositions suitable for the sensitization of tumors to radiation are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.